PHP
SGHT icon

Parkman Healthcare Partners’s Sight Sciences SGHT Stock Holding History

Parkman Healthcare Partners’s Portfolio SGHT Stock Details SGHT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-105,102
Closed -$1.28M – 93
2022
Q4 		$1.28M Buy
+105,102
New +$999K 0.34% 69

Other funds holding SGHT

DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Parkman Healthcare Partners's SGHT Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Sight Sciences (SGHT) in Q1 2023, closing a stake of 105,102 shares — an estimated $1.28M sold.

Parkman Healthcare Partners first reported a position in SGHT in Q4 2022 and held it in 1 quarter. The position peaked at $1.28M in Q4 2022. 75 funds tracked by Wall St. Rank hold SGHT as of Q1 2023.

  • Parkman Healthcare Partners reported no remaining Sight Sciences position as of Q1 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 105,102 Sight Sciences shares in Q1 2023, an estimated $1.28M.
  • Parkman Healthcare Partners first reported a position in Sight Sciences in Q4 2022 and held it in 1 quarter.
  • Parkman Healthcare Partners's Sight Sciences position peaked at $1.28M in Q4 2022.
  • 75 funds tracked by Wall St. Rank held Sight Sciences as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.